The State of Pneumococcal Disease Prevention

Slides:

Advertisements

Similar presentations

Antimicrobial resistance surveillance in Ireland Results of invasive Streptococcus pneumoniae infection (blood/CSF) surveillance (2009Q1-4) **** Data as.

Advertisements

2014 UPDATES FROM THE CDC’S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) William Schaffner, MD Professor of Preventive Medicine and Infectious Diseases.

Update on Pneumococcal Vaccines

ACIP Meeting Update November 4 th

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.

Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.

Jan T. Poolman, Ph.D. Director, Bacterial Vaccines R&D

Vaccines and Related Biological Products Advisory Committee Meeting

1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.

Epidemiology of Pneumococcal Disease in the U.S. in the Conjugate Vaccine Era Food and Drug Administration Center for Biologics Evaluation and Research.

Prevention of pneumococcal disease – What are the prospects? Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Allison McGeer,

Epidemiology of invasive pneumococcal disease in adults CDR Matthew R. Moore, MD, MPH Centers for Disease Control & Prevention U.S. Department of Health.

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.

Adult Immunization Rates January 21, 2016 VAC Joey Eavey, MSPH.

GREAT PLAINS AREA 2014 GPRA FINAL RESULTS & BEST PRACTICES Janelle Trottier, MSW, LCSW Health Systems Specialist.

 Thomas F. Koinis, MD, FAAFP  Duke Primary Care Oxford  February 9, 2016.

September 16, 2014 Bedford Senior Center Joyce Cheng RN Community Health Nurse Bedford Board of Health.

 Carolyn A. Parry, MPH CDC Public Health Advisor Montana Immunization Program 2016 Regional Immunization Workshops.

Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

Richard Zimmerman, MD, MPH, MS Anthony E. Brown, MD, MPH Valory N. Pavlik, PhD Krissy K. Moehling, MPH Jonathan M. Raviotta, MPH Chyongchiou J. Lin, PhD.

Improving Pneumococcal Vaccination Rates David Diamant MD, Molly Benedum MD Center for Family Medicine Aim The aim is to increase awareness of pneumococcal.

C. Jillian Tsai, Ph.D. Department of Preventive Medicine

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory.

Guidelines for Vaccinating Dialysis Patients BY: DR. JONAIDI ASSOCIATE PROF. OF INFECTIOUS DISEASES.

2016 Adult Immunization Update. David H

Pneumococcal vaccination in adults: PCV13?.. PPSV23?.. both??

Vaccines and Related Biological Products Advisory Committee Meeting

* LABORATORY-BASED SURVEILLANCE OF S. PNEUMONIAE INVASIVE DISEASE (IPD) IN CHILDREN: SEROTYPE DISTRIBUTION AND ESTIMATION OF VACCINES COVERAGE B. V. M.

Polysaccharide 23 (Pneumovax) & Conjugate 13 Now Togather as a New Reccomendation… If I am the one putting it in to practice, please don’t change any.

Jolianne Stone, MPH L Smithee, K Bradley, M McDermott

Toronto Invasive Bacterial Diseases Network

Texas Department of State Health Services Dr

Dengue Prevention in Asia

The Ohio State University, Columbus, Ohio

HPV-Related Disease: Separating Fact From Fiction

Adult Immunization: Making the Most of Everyday Opportunities

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period J. Liñares, C. Ardanuy, R. Pallares, A.

DENGUE VACCINE.

Immunizing the Older Adult: Challenges and Opportunities

ACIP Recommended Vaccines for Adults – By Age

Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia

Pneumococcal Disease Prevention in Children: Issues in the Era of PCVs

Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the.

Maternal Pertussis vaccination: Giving Newborns a head start

Meningococcal B Vaccination Implementing the ACIP Category B Recommendations.

Serogroup B Meningococcal Disease

National Gains If All States Achieved Top Rates* of Performance

Preventing HPV-related Disease: What Do the Latest Data Tell Us?

Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine E. Calbo, Á. Díaz, E.

IBD Increases Risk for Vaccine-Preventable Diseases

The role of vaccination in preventing pneumococcal disease in adults

Addressing Pneumococcal Disease in Latino Communities

National gains if all states achieved top rates* of performance

Immunization Throughout the Life Course: What Is the Clinician's Role?

Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Stefanie Desmet, Jan Verhaegen, Marc Van Ranst,

Cynthia Whitney MD MPH FIDSA Senior Subject Matter Expert, IHRC Inc.

Update on Shingles.

Daniel M. Musher, MD Mayo Clinic Proceedings

Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008) C. Esteva, L. Selva, M.F.

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non- universal vaccination coverage of the seven-valent conjugate vaccine

Clinical Microbiology and Infection

Many immigrants are susceptible to vaccine-preventable diseases upon arrival in Canada. Evidence indicates that 30%–50% of new immigrants are susceptible.

Contribution of Vaccines to Life-Course Event-Free Health

MenB Update: Communicating the Imperative With Parents

National Immunization Conference

Serotype 10A in Invasive Pneumococcal Disease (IPD) Surveillance in New Jersey, April – September 2009 Samantha Pitts, MD, MPH CDC/CSTE Applied Epidemiology.

The Expanding Role of Community Pharmacists in Identification of At-Risk Patients and Provision of Pneumococcal Vaccinations Ed Cohen, PharmD Immunization.

Invasive Pneumococcal Disease Serotypes After the Introduction of Pneumococcal Seven-Valent Conjugate Vaccine Arizona, Susan Goodykoontz, Daniel.

Presentation transcript:

The State of Pneumococcal Disease Prevention

The Basics of Pneumococcal Disease

Risk Factors for Pneumococcal Disease

Predictors of Death

Serotypes and Deaths

Percentage of Invasive Pneumococcal Disease Caused by Serotypes in 3 Pneumococcal Vaccines

Efficacy of Vaccines to Prevent IPD

PPV Efficacy Against Pneumococcal Pneumonia in Clinical Trials*

Vaccine Effectiveness in Older Adults

Cochrane Analysis 2013 PPSV

Changes in IPD Incidence by Age Group 1996-2007 (CDC Active Bacterial Core Surveillance)

Changes in IPD Incidence by Serotype Group Among Children Ages <5 Years

Changes in IPD Incidence by Serotype Group Among Adults Ages >65 Years

ACIP Recommendations for Use of PPSV and PCV 2012

ACIP Recommendations for Use of PPSV and PCV (Cont)

Pneumococcal Vaccine Coverage 2012

CAPiTA Study

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)